Celldex Therapeutics Inc (NASDAQ:CLDX) To Present Data Of 2 Clinical Programs

Posted by Kristi Scott October 22, 2013 0 Comment 1889 views


On Monday, Celldex Therapeutics, Inc (NASDAQ:CLDX) announced that the data from 2 of the company’s clinical-programs- the Phase-1 dose-escalation study, CDX-1127 & the Phase-2 recurrent-rindopepimut study, is slated to be  presented at 2 medical meetings. The first is at the Society for Immunotherapy of Cancer and the other at the Society of Neuro-Oncology. Celldex Therapeutics, Inc (NASDAQ:CLDX) also announced the communication-plan that the data-presentations will be centered on.

The block for data-presentation at the SITC will be lifted on Thursday, 7 November. This is when the time abstracts will be posted on the SITC site. Celldex Therapeutics, Inc (NASDAQ:CLDX) has 3 different abstracts on the CDX-1127 that have received acceptance for poster-presentation. In line with block-lift, the company will issue a press-release. This release will include the initial data that is included in the abstracts as well as the updated data that is scheduled to be presented at the poster sessions.

Monday’s trading

In Monday’s trading, Celldex Therapeutics, Inc (NASDAQ:CLDX) dropped by 9.07%. The opening price of the shares was $25.47, which climbed to an intraday high of $26.00 and dipped to a close of $23.46. Approximately 5.61 million shares were traded on Monday while an average volume of 3.41 million shares were traded over a 30 day period. The 52-week low of Celldex Therapeutics, Inc (NASDAQ:CLDX) shares is $5.02 and its 52-week high is $38.84. The company has a market capitalization of $1.90 billion.

About the company

Celldex Therapeutics, Inc (NASDAQ:CLDX) is a bio-pharmaceutical company. It focuses on developing and commercializing numerous immunotherapy technologies that are used to treat cancer and various other very difficult-to-treat diseases. Celldex Therapeutics, Inc (NASDAQ:CLDX)’s drug candidates are CDX-110, CDX-011 & CDX-1127. CDX-110, is the immune-therapeutic vaccine. It targets tumor-specific molecule, epidermal growth-factor receptor variant-III. CDX-1127 is a human-monoclonal antibody that targets the CD27. CD27 is the co-stimulatory molecule that exists on T-cells and is over-expressed in specific lymphomas & leukemia.



About Kristi Scott

Kristi Scott joined GDP Insider in 2005 as a Wall Street reporter for the Business and Market section. Kristi covers the stock market, financial markets and personal finance. Her awards have come from the National Federation of Professional Writers, the Ohio Newspaper Association, the Cleveland Press Club, the Society of Professional Journalists and Suburban Newspapers of America. Kristi was named SNA's national Journalist of the Year

View all post by Kristi Scott Visit author's website

Write Your Comment